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AstrocyteAccumulation of misfolded forms of microtubule associated, neuronal protein tau causes neuroﬁbrillary degen-
eration typical of Alzheimer's disease and other tauopathies. This process is accompanied by elevated cellular
stress and concomitant deregulation of heat-shock proteins. We used a transgenic rat model of tauopathy to
study involvement of heat shock protein 27 (Hsp27) in the process of neuroﬁbrillary degeneration, its cell type
speciﬁc expression and correlation with the amount of insoluble tau protein aggregates. The expression of
Hsp27-mRNA is more than doubled and levels of Hsp27 protein tripled in aged transgenic animals with tau pa-
thology. The data revealed a strongpositive and highly signiﬁcant correlationbetweenHsp27-mRNAand amount
of sarkosyl insoluble tau. Interestingly, intracellular accumulation of insoluble misfolded tau protein in neurons
was associated with overexpression of Hsp27 almost exclusively in reactive astrocytes, not in neurons. The topo-
logical dissociation of neuronally expressed pathological tau and the induction of astrocytic Hsp27, GFAP, and
Vimentin alongwith up-regulation ofmicroglia speciﬁcmarkers such as CD18, CD68 and C3 point to cooperation
of astrocytes, microglia and neurons in response to intra-neuronal accumulation of insoluble tau. Our data sug-
gest that over expression of Hsp27 represents a part of microglia-mediated astrocytic response mechanism in
the process of neuroﬁbrillary degeneration, which is not necessarily associated with neuroprotection and
which in contrary may accelerate neurodegeneration in late stage of the disease. This phenomenon should be
considered during development of disease modifying strategies for treatment of tauopathies and AD via regula-
tion of activity of Hsp27.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Sporadic and familial tauopathies represent a signiﬁcant group of
neurodegenerative conditions; among them Alzheimer's disease
(AD) is the most common form of dementia [43]. Abnormally modi-
ﬁed, misfolded neuronal protein tau is the main pathological factor
inducing neurodegeneration in tauopathies. Its intracellular accu-
mulation in the form of argyrophilic neuroﬁbrillary lesions (neuroﬁ-
brillary tangles (NFTs) and neuropil threads) is a deﬁning feature of
AD and several other neuropsychiatric disorders [9,18,52,53].
Misfolding of tau is the result of either mutations in tau gene [21,
47] or aberrant posttranslational modiﬁcations of tau protein,
resulting mainly from truncation [5,20,39,40,59] and/or abnormal
phosphorylation [19,24]. Insoluble abnormal tau protein depositionsgy, Slovak Academy of Sciences,
2 5478 8100; fax: +421 2 5477in human brain start developing very early in life—during childhood
and puberty. It can be found in lower brainstem ﬁrst as a pre-tangle
material in proximal axons and somatodendritic compartment of
neurons in locus coeruleus, which later spreads into cortical areas
and converts into argyrophilic lesions [7,8]. The ﬁbrillary tau forms
represent a critical pathogenic factor, as shown in cellular models
[4,26,61], while NFTs were proposed to have a cyto-protective effect
[10,41]. The pathologically modiﬁed tau protein, which appears prior
to or during the transition frommonomeric state to highermolecular
oligomers is considered a critical toxic intermediate that should be
therapeutically targeted [32].
The up-regulation of small molecular weight heat shock protein
(Hsp27) has been detected in both neurons and astrocytes of different
animal species under stress and in neurodegenerative conditions [2,
14,17,22,23,27,33,57]. The elevated levels of Hsp27 in the cortex of
brains from AD patients were revealed by immunohistochemical and
biochemical studies. Hsp27-positive astrocytes were detected in close
proximity to senile plaques and neuroﬁbrillary tangles, and also
various glial cells in different tauopathies were found Hsp27-positive
[1,33,44,46,48,58]. Hsp27 was described as a direct interaction partner
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vitro itwas found to facilitate degradation and dephosphorylation of ab-
normally phosphorylated tau [45]. Furthermore, overexpression of
Hsp27 ameliorates joint toxic effects of mutant APP and PS1 proteins
in amousemodel [54]. Small heat shock proteins, a part of protein qual-
ity control machinery, may serve as the ﬁrst line of defense against
stress-induced cell damage by maintaining proteins in a folding-
competent state [25]. Probably as a result of these protective properties,
Hsp27 has roles in promotion of neuron survival and neurite outgrowth,
cell differentiation and inhibition of oxidative damage and apoptosis [3,
42,56]. Mutations in the HSPB1 gene could lead to neurodegenerative
disorders [34]. Themolecularmechanisms underlyingHsp27 neuropro-
tection in speciﬁc types of brain cells remain under investigation, its role
as neuro-protective factor in protein aggregate-associated neurodegen-
eration has not yet been fully elucidated and is controversial especially
in chronic neurodegenerative diseases [6,49].
Here we investigated whether the pathological truncated tau
protein induces expression of small heat shock protein Hsp27 in rat
model of neuroﬁbrillary degeneration. We have analyzed expression
levels of Hsp27 in various stages of neuroﬁbrillary pathology and cell
type speciﬁc localization of Hsp27. Our data demonstrate that forma-
tion of insoluble truncated tau protein, not soluble tau, is associated
with elevated levels of Hsp27 gene and protein expression. More im-
portantly, we present clear cell type speciﬁc dissection of neuroﬁ-
brillary pathology and Hsp27 expression. Surprisingly, Hsp27 is not
induced in the neurons that bear aggregated misfolded tau proteins
but almost exclusively in astrocytes of degenerated brain regions.
The cell type speciﬁc expression pattern should be considered during
development of disease modifying strategies for treatment of
tauopathies and AD based on regulation of activity of heat shock pro-
teins, speciﬁcally Hsp27.
2. Material and methods
2.1. Animals expressing human truncated tau protein
The transgenic rat strain expressing truncated human tau protein
has been described elsewhere [31,60] Brieﬂy, the transgene was pre-
pared by ligation of a human cDNA encoding truncated tau protein
(aa151-391,4R) into the mouse Thy-1 gene immediately downstream
of the brain-enhancer sequence replacing thymus enhancer. Transgenic
rats were generated by pronuclear injection of 1-day-old rat embryos.
All rats were housed under standard laboratory conditionswith free ac-
cess to water and food, and were kept under diurnal lighting conditions
(12 h light: dark cycles, with light starting at 7:00 am). The experiments
were approved by the State Veterinary and Food Committee of Slovak
Republic, and by Ethic Committee of Institute of Neuroimmunology,
Slovak Academy of Sciences. The animals were anesthetized and
sacriﬁced according to ethical guidelines tominimize pain and suffering
of experimental animals. Efforts were made to minimize the number of
animals utilized.
2.2. RNA extraction and quantitation by RT-qPCR
Brain samples were dissected from control and transgenic rats, im-
mediately frozen in liquid nitrogen and stored at −80 °C. Total RNA
was isolated by TRI Reagent extraction method according to manu-
facturer's protocol (Sigma-Aldrich, USA). Resulting RNA was brieﬂy air-
dried, dissolved in 100 μl of RNAse-free water (Qiagen, Germany). RNA
samples were kept frozen at−80 °C. Integrity of isolated total RNA sam-
ples was determined by Agilent 2100 Bioanalyzer using a RNA 6000
Nano Labchip kit (Agilent Technologies, USA). For transcriptomic analy-
sis we have used high quality RNA samples (RNA Integrity Number;
RIN = 7.5–8.7).
Synthesis of the ﬁrst strand was carried out using the High capacity
cDNA reverse transcription kit (Applied Biosystems, USA) according tothe manufacturer's recommendations. Levels of Hsp27, GFAP, Vim, C3,
CD18 and CD68 mRNA were determined using qPCR with GAPDH as a
standard. Following TaqMan primer assays (FAM for target genes and
VIC for reference gene) were used for gene expression analysis: Hsp27,
Rn00583001_g1; GFAP, Rn00566603_m1; Vim, Rn00579738_m1; C3,
Rn00566466_m1; CD18, Rn01427948_m1; CD68, Rn01495634_g1;
and reference gene GAPDH, Rn99999916_s1 (Applied Biosystems).
Comparative ddCt analysis was performed in order to compare
gene expression in transgenic and wild type animals. Results are
expressed as a fold change of target gene mRNA level in transgenic
animals compared to an arbitrarily selected individual from the
non-transgenic control rat group.
2.3. Extraction of sarkosyl insoluble tau
Sarkosyl insoluble tau (SiT) was isolated from brain tissues of
6 month old rats. Frozen brain samples were homogenized in 10 vol-
umes of ice-cold extraction buffer [SL buffer: 20 mM Tris, pH 7.4;
800 mM NaCl; 1 mM ethylenglycoltetraacetic acid (EGTA)]; 1 mM
ethylenediaminetetraacetic acid (EDTA); 0.5% β-mercapthoethanol,
10% sucrose; 1 mM Na3VO4; 20 mM NaF; supplemented with the
Complete without EDTA (Roche Diagnostics, USA) protease inhibi-
tors using an OMNI TH tissue homogenizer (OMNI International,
USA). After incubation on ice for 5 min the homogenates were
cleared by centrifugation at 20,000 ×g for 20 min at 4 °C. The super-
natants were collected and the total protein concentration was de-
termined using the BioRad protein assay (BioRad, USA). This
supernatant was designed 1S. Solid sarkosyl (N-lauroyl sarcosine,
Na-salt, Sigma) was added to 1S supernatant to achieve 1% concen-
tration and stirred for 1 h. This material was centrifuged at
100,000 ×g for 1.5 h at room temperature (RT). Supernatant was col-
lected and pellets were gently rinsed with 1 ml of the SL buffer and
centrifuged again at 100,000 ×g for 20 min at RT. The pellets were
designated 2P. Samples for SDS-PAGE were prepared by dissolving
2P preparation in 1× SDS sample loading buffer in 1/50 volume of
the 1S.
2.4. Glial primary cell culture and aggregation of tau
Mixed glial culture containing astrocytes and microglia was pre-
pared from cerebral cortices of newborn Sprague Dawley rats
(1 day old). Cells were cultured in DMEM containing 10% FCS and
2 mM L-glutamine for 7 days and treated for 24 h with 1 μM heparin-
aggregated truncated tau protein, which was prepared according to
previously published protocol [35].
2.5. Western blotting
The expression level of total human truncated tau in the transgenic
rats was determined by Western blot analysis using protein extracts
from experimental animals. Sarkosyl insoluble tau proteins in 2P
preparation were analyzed on 10% SDS-PAGE gel and Western blot
as described previously [31]. The membranes were probed with
anti-tau primary antibody DC25 (pan-tau monoclonal antibody
DC25 recognizing residues 347–354, Axon Neuroscience SE,
Bratislava, Slovakia) [38,60], and other primary antibodies listed in
Table 1. Incubation with goat anti-mouse HRP-conjugated secondary
antibody (Dako, Denmark) was subsequently performed. Labeled
secondary antibodywas visualizedwith a chemiluminescence detec-
tion system (Pierce, USA), and the signal was recorded with a
LAS3000 CCD imaging system (Fujiﬁlm, Japan). Densitometric data
analysis and relative quantiﬁcation of Western blots were performed
by AIDA Biopackage software (Raytest, Germany) as described [12].
The amount of Hsp27 protein was analyzed in the 1S preparation,
and the relative level of anti-Hsp27 signal was normalized to the
Gapdh (both antibodies purchased from Abcam, USA).
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Preparation of samples was performed as described previously
[50]. Rats were deeply anesthetized with ketamine–xylasine,
perfused intracardially, their brains were removed and post-ﬁxed
overnight in 4% paraformaldehyde in phosphate-buffered saline,
cryoprotected with 15% and 25% sucrose solutions (subsequently
overnight), frozen in 2-methylbutane (30 s at −42 °C) and trans-
ferred to dry ice. Sagittal brain sections (40 μm thick) were cut on a
Leica CM1850 cryomicrotome.
2.7. Immunohistochemistry
For stereological analysis, every 12-th section was included in the
series (section sampling fraction = 1/12). Brain tissue samples were
treated with 80% formic acid (30 s.) to retrieve the antigen accessi-
bility. Tissue sections were incubated with primary antibodies anti-
Hsp27 (Abcam, UK), anti-GFAP (Abcam, UK) or anti-NeuN antibody
(Millipore, USA) overnight at 4 °C. Sections were immunostained
using the standard avidin–biotin-peroxidase method (Vectastain
ABC kit) with VIP as chromogen. Finally, sections were counter-
stained by methyl green (Vector, USA). All the antibodies used in
this study are listed in Table 1.
2.8. Stereological quantiﬁcation
For stereological quantiﬁcation, male rats of transgenic line TG72
(n = 3) in the terminal stage of transgenic phenotype and age-
matched non-transgenic littermates WT controls (n = 3) were
used. Stereological quantiﬁcation of the numbers of Hsp27-positive
neurons and astrocytes, GFAP-positive astrocytes and NeuN-
positive neurons was performed using an optical fractionator ap-
proach on a modiﬁed light microscope (Olympus BX51) equipped
with a computer-based stereological system (StereoInvestigator;
MicroBrightField, USA). The region of interest was selected at low
magniﬁcation (objective 4× UPlanFI) and counting was performed
at high magniﬁcation using an objective with high numerical aper-
ture (60× oil immersion objective, Olympus, UPlanFI, NA = 1.25)
and oil condenser (Olympus, UAAC, PlanApo, NA = 1.40). Parame-
ters of the stereological analysis (dissector base, sampling grid)
were chosen according to density of the particular structure in the
tissue−sparse Hsp27-positive cells required a denser grid than fre-
quent GFAP-positive astrocytes, to ensure precise analysis with ap-
propriately low coefﬁcient of error. The parameters of stereological
analysis are described in table 2.
2.9. Immunoﬂuorescence
Co-localization experiments were performed on free-ﬂoating
sections using the standard immunoﬂuorescent staining procedure.
After 20min in 1% sodium borohydrate and 1 h blocking in 5% bovine
serum albumin (Sigma), sections were incubated with primary anti-
GFAP (1:500), AT8 (1:1000) and anti-Hsp27 (1:500) antibodies
overnight at 4 °C. After washing, the sections were incubated for
1 h in secondary antibodies (1:1000) conjugated either with AlexaTable 1
List of primary antibodies used in the study.
Antibodies Species Speciﬁcity
AT8 Mouse Phosphorylated tau protein (Ser-202,
DC 25 Mouse Tau protein, aa347–353
GAPDH Mouse Glyceraldehyde-3-phosphate dehydro
GFAP Mouse Glial ﬁbrillary acidic protein
Hsp27 Rabbit Heat shock protein 27
NeuN Mouse Neuron-speciﬁc proteinFluor 546 or Alexa Fluor 488 ﬂuorescent dyes (Invitrogen, Eugene,
Oregon, USA). After washing, the sections were mounted onto slides
using Vectashield mounting medium (Vector laboratories, USA) and
examined with laser scanning confocal microscope LSM 710 (Zeiss).2.10. Statistical analysis
Graphpad Prism (version 4.03 for Windows; Graph Pad Software,
San Diego, CA, USA) was used to carry out the statistical analysis. Differ-
ences were analyzed with unpaired Student's t-test. Correlation analy-
ses were performed adopting non-parametric Spearman correlation.
Results were considered to be statistically signiﬁcant if p b 0.05.3. Results
3.1. Hsp27 is signiﬁcantly upregulated in aged rats expressing truncated tau
protein
Transgenic rat strain (Tg line #72) used in this study has been de-
scribed elsewhere [31,60]. Expression of truncated tau protein in Tg
line #72 leads to development of AD-like tau pathology in neurons of
brainstem and spinal cord. To study the Hsp27 expression in the brain
area directly affected by neurodegeneration, we performed all experi-
ments on the whole brainstem tissue, which includes midbrain, pons
and medulla oblongata. Firstly, we determined the developmental pro-
ﬁle of Hsp27 in transgenic (TG) animals and their wild type (WT) litter-
mates on Western blot (Fig. 1a). Very low amount of Hsp27 was found
in early postnatal period (12 days) in both strains. The levels of Hsp27
changed in adulthood, exhibiting an age-dependent gradual increase
with no apparent difference between TG animals and WT controls up
to the 4th month of age. However, in the age of 6 months when patho-
logical changes start to appear in transgenic population [31], the level of
Hsp27 in TG animals suddenly increased to 2.8-fold of control animals
value (Fig. 1b). To conﬁrm these data, we repeated the experiment on
larger group of animals. We have analyzed Hsp27 protein and mRNA
level focusing on two developmental stages (4 and 6 months). We
found slightly elevated Hsp27 at the 4th month of age in TG animals,
whereas later, at the 6th month of age, we observed a 3-fold increase
of Hsp27 levels compared to WT (Fig. 1c, d). The Hsp27 mRNA was
slightly elevated in TG animals already at the age of 4months (nearly
20% increase in comparison to WT). By the 6th month of age the ex-
pression of Hsp27 mRNA in TG animals has increased dramatically
and was found about 2.3 times higher in comparison to WT animals
of the same age (Fig. 1e). Interestingly, the level of soluble transgenic
truncated tau protein remained stable in the adulthood of TG ani-
mals, whereas the amount of insoluble tau protein forms gradually
increased as TG animals got older (months 2–6, Fig. 1f, g). In conclu-
sion, Hsp27 mRNA and protein are signiﬁcantly overexpressed in the
brainstem of TG animals and this upregulation occurs concurrently
with the increase of insoluble tau, independently on the pool of sol-
uble transgenic tau protein. These data indicate that Hsp27 is in-
duced by insoluble misfolded tau proteins and not by the soluble,
although abnormal, tau.Dilution Source
Thr-205) 1:1000 Thermo Scientiﬁc (Cat. MN1020)
1:1000 Axon Neuroscience
genase 1:2000 Abcam (Cat. 9484)
1:500 Abcam (Cat. ab10062)
1:500 Abcam (Cat. ab12351)
1:500 Millipore (Cat. MAB377)
Table 2
Parameters of the stereological analysis.
Dissector Sampling
Base Height Grid UGZ BA t
Structure quantiﬁed (antibody) (μm × μm) (μm) (μm × μm) (μm) (μm) (μm) ∑OD ∑Q- CE
Astrocytes (Hsp27) 80 × 80 15 500 × 500 2 40 22.2 2009 1144 0.085
Neurons (Hsp27) 80 × 80 15 500 × 500 2 40 22.2 2009 54 0.174
Astrocytes (GFAP) 70 × 70 15 900 × 900 2 40 21.2 629 1348 0.026
Neurons (NeuN) 70 × 70 15 600 × 600 2 40 20.8 1431 3169 0.034
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aggregated tau protein in transgenic animals
Development of insoluble tau protein, designed as sarkosyl-
detergent insoluble pool of tau and its accumulation in affected brain
areas is a prominent sign of neuroﬁbrillary degeneration in human
tauopathies. Similarly, in the rat Tg line #72 the load of sarkosyl insolu-
ble tau protein (SIT) reﬂects the stage of neuroﬁbrillary pathology and
correlates with the life span of the TG animals [31]. To evaluate the rela-
tionship of Hsp27 expression and the stage of neuroﬁbrillary pathology
we have quantiﬁed the Hsp27 mRNA and SIT by RT-qPCR and Western
blot, respectively, in the brainstem samples from a cohort of six-months
old TG animals (n = 20, Fig. 2). The amount of Hsp27 mRNA in TG ani-
mals was 1.35 to 3.8 higher than the amount of mRNA detected in WT
animals of the same age (compare with Fig. 1e), and the proﬁle of
Hsp27 mRNA overexpression in TG animals mirrored the highly vari-
able proﬁle of SIT in the contralateral brain region (Fig. 2a). Moreover,
the Hsp27 mRNA fold increase strongly correlated with the amount of
SIT, indicating an interplay between the expression of Hsp27 and theFig. 1.Protein andmRNA levels of Hsp27 are signiﬁcantlyupregulated in aged rats expressing tru
of Hsp27 expression during development (a, b). Detailed comparison ofWT and TG animals at 4
old TG animals (c, d). Expression of Hsp27 proteinwas normalized to Gapdh level (n=6, ***P b
analysis (e), **P= 0.002. Soluble tau protein expression in TG animals was analyzed by pan-tau
binant tau protein isoforms (6i) were used as a control. Compared to the stable expression of so
(g) as determined by DC25.degree of neuroﬁbrillary pathology in transgenic animals (Fig. 2c;
p = 0.0004; r = 0.72).
3.3. Hsp27 is predominantly overexpressed in reactive astrocytes located in
regions with tau pathology, rarely in neurons
Immunohistochemical staining revealed that in control rat brains,
where no tau pathology was observed (Fig. 3a), Hsp27 was almost not
present in astrocytes (Fig.3b) expressing GFAP protein (Fig.3c). On the
contrary, in transgenic rat brain, where extensive neuroﬁbrillary degen-
eration was found in the reticular formation of the brainstem (Fig. 3d),
we detected a high number of reactive astrocytes expressing Hsp27
(Fig. 3e) and GFAP (Fig. 3f). Stereological quantiﬁcation demonstrated
signiﬁcant increase of the number of GFAP-positive (reactive) astro-
cytes in TG brains compared to WT animals (1.7-fold increase;
p b 0.002; Fig. 3g). Further, we observed a selective increase of Hsp27-
positive reactive astrocytes in transgenic rat brains (16-fold increase;
p b 0.01; Fig. 3h). Interestingly, more than 30% of the GFAP-positive as-
trocytes were also immunoreactive to Hsp27 in transgenic rat brain,ncated tauprotein.Western blot analysis of brainstemprotein extracts revealed theproﬁle
th and 6thmonths of age showed signiﬁcant increase of Hsp27 protein level in 6thmonth
0.001). The upregulation of Hsp27 at the protein level was conﬁrmed bymRNA expression
antibody (DC25) recognizing rat endogenous and human truncated tau forms (f). Recom-
luble tau proteins the sarkosyl insoluble tau fraction increased with the age of TG animals
Fig. 2.Hsp27mRNA correlateswith insoluble, aggregated tau protein level.Western blot analysis using the pan tau antibodyDC25 revealed different amounts of insoluble and aggregated
tau protein in brainstem of experimental animals (a). The Hsp27 mRNA fold change in TG animals (b) corresponds to the amount of the insoluble tau. We found statistically signiﬁcant
correlation between expression of Hsp27 mRNA and amount of sarkosyl insoluble tau (***P = 0.0004, r = 0.7167, n = 20).
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to both markers (p b 0.05) (Fig. 3i). Confocal study supported our im-
munohistochemical data showing that signiﬁcant part of GFAP positiveFig. 3. Regional distribution of Hsp27 positive astroglia is parallel that of neuroﬁbrillary tangle
positive tau pathological lesions (a). Hsp27 positive astrocytes were present occasionally (b). P
genic rat brain we found large number of AT8 positive neuroﬁbrillary tangles and neuropil thre
pathology, numerousHsp27 andGFAP positive astrocyteswere found (e, f). Stereological quanti
of transgenic rats (g, h). We found that on average every 3rd GFAP positive astrocyte expresseastrocytes displayed increased expression of Hsp27 in TG animals
(Fig. 4a–c). Moreover, we found that Hsp27 positive reactive astroglial
cells were localized in a close proximity of AT-8 positive neuroﬁbrillarys in transgenic rat brainstem. In the brainstem of control rat we did not observe any AT8
anel c shows GFAP positive astrocytes in control non transgenic rats. In contrast, in trans-
ads, mainly in the nuclei of reticular formation (d). In the area affected by neuroﬁbrillary
ﬁcation showed increased number of GFAP andHsp27 positive astrocytes in the brainstem
d also Hsp27 protein (i). Scale bar: 100 μm.
Fig. 4. Confocal microscopy showed that Hsp27 positive astrocytes are distributed in a close proximity of tau neuroﬁbrillary lesions. A subgroup of GFAP positive astrocytes expressed high
levels of Hsp27 (a–c). Hsp27 positive astrocytes were localized close to the AT8-positive tau neuroﬁbrillary tangles (d–f) and dystrophic neurites (g–i). However, intraneuronal co-local-
ization of Hsp27 and AT8 signals was very rare (f). Scale bar: 100 μm.
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co-localization of Hsp27 signal with degenerating neurons was very
rare (Fig. 4f).
3.4. Tau neurodegeneration did not reduce the number of Hsp27 neurons in
the brainstem of transgenic rats
In order to identify the impact of tau neurodegeneration on total
neuronal numbers we stained both transgenic and control rat brains
with neuron speciﬁc marker Neu-N (Fig. 5a,b). We found no difference
in total number of NeuN-positive neurons when comparing TG andWT
animals (Fig. 5e). It is known, that Hsp 27 is constrictively expressed in
several sensory and motor neurons in the brainstem and spinal cord. In
both control and transgenic rats,we have found extensiveHsp27 immu-
noreactivity in following brainstem nuclei: nucleus ambiguous, trigem-
inal motor nucleus, mesencephalic nucleus of the trigeminal nerve and
facial nucleus (Fig. 5c, d). Interestingly, these types of neurons usually
do not develop neuroﬁbrillary pathology and no activated Hsp27
immunopositive astrocytes were present in close proximity of these
neurons. We found a non-signiﬁcant increase of Hsp27-positive neu-
rons in TG rats (Fig. 5f). Overall, only 0.9% and 1.1% of all neurons
were Hsp27-positive in WT and TG animals, respectively (Fig. 5g).
3.5. Aggregated tau induces Hsp27 expression in astroglial cell cultures
To provide further evidence for an induction of Hsp27 expression in
astrocytes by aberrant tau protein,we exposed primary culture of astro-
cytes fromWT animals to the in vitro aggregated human truncated tau
protein prepared by incubation of recombinant tau with heparin [35].As shown on Fig. 6a, heparin-aggregated truncated tau induced Hsp27
andGFAP proteins expression after short term (24h) incubation. The in-
crease in the level of both proteins was statistically signiﬁcant (Fig. 6b,
c). This experimental design mimics the inﬂuence of extracellular tau
(released from neurons accumulating pathological tau) on astrocytes,
and suggests that extracellular forms of tau may induce the expression
of Hsp27 in astrocytes observed in TG animals.
3.6. The level of sarkosyl insoluble tau correlates with increased expression
of astroglial and microglial markers in transgenic rat brain
To further characterize the relation of SIT and glial cells activation,
we performed transcriptomic analysis of selected glial cell speciﬁc
markers and key proteins of immune system in the brainstem tissue
samples. We found highly signiﬁcant positive correlations between
the amount of SIT and mRNA levels of reactive astrocytes markers
such as GFAP and Vimentin (Fig. 7a), as well as themarkers of activated
microglia, complement C3, surface antigens CD18 andCD68 (Fig. 7b). As
expected, we observed strong and statistically signiﬁcant correlations
also between the mRNA levels of Hsp27 and all ﬁve examined markers
(GFAP, Vimentin, C3, CD18 and CD68; Supplement Fig. 1). Our data sug-
gest that it is astrocytes andmicroglia that respond to the intraneuronal
accumulation of misfolded tau proteins via induction of an immune-
stress response pathway including Hsp27.
4. Discussion
Posttranslational modiﬁcations of tau protein, such as patholog-
ical hyperphosphorylation and proteolytical truncation, lead to
Fig. 5. Neuroﬁbrillary pathology did not reduce the number of Hsp27 positive neurons in transgenic rat brain. Neuronal cells were labeled by neuronal marker Neu-N in both control and
transgenic rat brain (a, b). The Hsp27 antibody recognized the same motor and sensory neuronal nuclei in control and transgenic rat brains (c,d). Stereological quantiﬁcation of Neu-N
positive brainstem neurons revealed the same neuronal number in control and transgenic rat brainstem (e). Similarly, the number of Hsp27 positive neurons in the brainstemwas almost
identical in control and transgenic rats (f). Number of Hsp27 positive Neu-N neuronswas very low (about 1% of total neuronal population) and similar in control and transgenic brainstem
(g). Figures (a–d) show Neu-N and Hsp27 staining of the facial nucleus in the rat brainstem. Scale bar: 50 μm.
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early events inADandoccurs prior to formation of neuroﬁbrillary tangles
[5,37,40]. Recently,we and others showed that expression of the truncat-
ed tau protein induces neurodegeneration to a different extent in rodent
experimental models [16,31,36,51,60]. Transgenic rats expressing
human truncated tau develop neuroﬁbrillary degeneration, similar to
that observed in human tauopathy and AD [16,31,60], progressiveFig. 6.Aggregated tau protein induces Hsp27 expression in astroglial cells in vitro. Incubation of
regulation ofHsp27 andGFAPprotein levelswhen compared to control cells (a). Expression ofH
(*P = 0.0166) and 5.5-fold increase of GFAP (*P = 0.0127), respectively.decline of sensorimotor functions and impairment of several reﬂexes
[28] and elevated oxidative stress [11]. These ﬁndings are interesting
particularly when compared to recently described transgenic rats ex-
pressingmutated tau protein (P301L), which do not display any obvious
neuroﬁbrillary pathology, neuronal loss or glial activation [29].
An age dependent increase in the amount of sarkosyl-insoluble tau
and the number of neuroﬁbrillary tangles are the typical features ofheparin-aggregated truncated tau proteinwith astroglial cells for 24 h led to signiﬁcant up-
sp27 andGFAPproteinwasnormalized toGapdh (b, c) revealing 1.3-fold increase ofHsp27
Fig. 7. Increased astrocyte and microglia markers correlate with sarkosyl insoluble tau. Transcriptomic analysis revealed signiﬁcant upregulation of mRNA expression levels of astrocyte
markers (a) GFAP (2.1-fold, ***P b 0.001) and Vimentin (1.7-fold, **P = 0.0026) and up-regulation of markers of microglia (b) C3 (3.4-fold, ***P b 0.0001), CD18 (2.6-fold, ***P b 0.0001)
and CD68 (3.9-fold, ***P b 0.0001). Both astrocyte markers (GFAP, Vim) and all three microglial markers (C3, CD68, CD18) signiﬁcantly positively correlated with amount of sarkosyl in-
soluble tau (n = 20).
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the load of sarkosyl insoluble tau proteins are related to the stage of the
disease and variability in this parameter allows for performing correla-
tion studies using the animals of same age. It was shown, that expres-
sion of Hsp27, one of the small stress-inducible/associated proteins
correlates with the severity of AD-speciﬁc morphological changes, and
also with the duration of dementia [44,46]. Consistent with these ob-
servations, we detected a strong induction of Hsp27 at both mRNA
and protein levels in our rat model. Developmental increase in the
level of Hsp27 was demonstrated recently using rTg4510 transgenic
mouse model of tauopathy, however this increase between adoles-
cence and adulthood was evident also in control mice, and the tau
dependent acceleration of Hsp27 was very modest [15]. In our rat
model we observed a slight age-associated increase in the amount
of Hsp27 between 2 and 4 months of age. However, in contrast to
the P301L mice [15], the level of Hsp27 in double truncated trans-
genic rats was clearly tau-dependent and was about 3-fold higher
than in age matched non-transgenic controls, at both the transcrip-
tional and translational levels.In 6 month old transgenic rats, the loads of insoluble tau protein
correlated strongly with the levels of Hsp27. This relationship corre-
sponds to and extends the phenomenon observed in experimental
animals and in human diseased brain tissue [8,15,44]. Here we dem-
onstrated for the ﬁrst time that the amount of Hsp27 increased pro-
portionally to the load of insoluble tau accumulated in the brain. Our
ﬁndings are in contrast to data of others [30,45] who showed previ-
ously a direct interaction of Hsp27with phosphorylated tau from AD.
These authors [30,45] worked with human material and did not
show cell type speciﬁcity of Hsp27 expression in the brain. In our ex-
periments misfolded tau does not come in contact with Hsp27, yet
strongly induces its expression in adjacent astrocytes.
We also found strong correlations of insoluble tau with markers
typical for astrocytes and microglia, such as GFAP, Vimentin and
complement components C3, CD18, CD68, respectively. We have
demonstrated previously that C4, CD11b/CD18, CD68 are present
onmicroglial cells [50], therefore, here we have focused on analyzing
the presence of Hsp27 in astrocytes and degenerating neurons. We
found that expression of Hsp27 was located almost exclusively in
Fig. 8. Proposed interplay and concerted actions between neurons, astrocytes andmicroglia, induced by expression of pathologically truncated tau protein. Posttranslationallymodiﬁed tau
protein induces intraneuronal accumulation of high molecular weight tau oligomers and insoluble aggregates. This phenomenon is accompanied with deterioration of neuronal function
and axonal damage. During this processmicroglial cells are activated and neuroinﬂammatory cascades are involved. Subsequent or simultaneous activation of astrocytesmay lead to neu-
roprotection via production of beneﬁcial growth factors and/or through activation of chaperonemachinerywhichmay result in increased cell division of neuroprotective astrocytes. How-
ever, over time the protective phase of neuroinﬂammation turns to chronic inﬂammatory process and the neuroprotective function of astrocytes is inhibited and followed by accelerated
neurodegeneration.
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in close proximity of degenerating neurons, we found very rare co-
localization of Hsp27 with speciﬁc markers of degenerated neurons. It
was published that Hsp27 is expressed in astrocytes and oligodendrog-
lia in tauopathies with extensive glial pathology [13,22,23,33], however
in ourmodel there is no expression of pathological tau in astrocytes and
other glial cells. The pathological tau in the rat transgenic model is
expressed exclusively in neurons (driven by Thy1 promoter). Induction
of Hsp27 expression in this model is therefore mediated indirectly ei-
ther via activatedmicroglia expressing immune markers or by stimula-
tion of astrocytes by extracellular tau, which could be released from
degenerating neurons (Fig. 8). The transgenic rat model therefore rep-
resents a unique experimental tool with cell type speciﬁc and topolog-
ically dissociated neuroﬁbrillary pathology and expression of Hsp27.
Our data point to the speciﬁc signaling between affected neurons and
activated astrocytes, which could be mediated via e.g. chemokines
and/or cytokines and which deserve further investigation (Fig. 8).
Based on our results we suggest that the role of Hsp27 although
originally protective may participate on activation of astrocytes par-
adoxically leading to inhibition of neuroprotective role of astrocytes,
which can be observed in chronic neurodegenerative diseases such
as tauopathies and AD [55]. This could lead to further impairment
of neuronal functions and acceleration of pathogenesis. Further analysis
of animals with simultaneous overexpression of pathological forms of
tau and down- or up-regulated expression of Hsp27 could shed more
light on the neuroprotective/neurotoxic role of Hsp27 and intercellular
signaling in the course of neuroﬁbrillary degeneration.
In conclusion, we have demonstrated at both the transcriptional and
translational levels that accumulation of sarkosyl insoluble tau strongly
correlates with elevated expression of Hsp27, despite their localizations
in different cell types. The activated chaperone is localized almost exclu-
sively in activated astrocytes, while NFTs are exclusively produced in
neurons. The role of Hsp27 in tauopathies may therefore be mediated
indirectly and is different from the canonical role of this chaperone,
e.g. folding competency, anti-apoptotic or antioxidant, since Hsp27
does not come into contact with the pathogenic molecule. Hsp27 can
be used as a neuropathological marker of activated astrocytes indegenerative diseases such as tauopathies. We suggest that the
transgenic rat model employed in this study can be efﬁciently used
for investigation of intercellular signaling between microglia, astro-
cytes and neurons.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.03.003.
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